Munich-based healthtech company dehaze has closed a €3.2 million seed funding round to build AI tools that detect chronic diseases before they become expensive problems. The round was led by YZR Capital and DN Capital, with participation from Angel Invest, Zoho, and Better Ventures.
The startup’s platform uses causal AI to analyze massive amounts of patient data, helping healthcare insurers spot people who might develop chronic conditions. The goal is simple: catch diseases earlier when they’re easier and cheaper to treat.
How does it work?
Dehaze’s system processes different types of healthcare data at scale and provides insights that both doctors and insurers can use to make decisions. Unlike chatbot or dashboard solutions, the company built what it calls a “foundational AI model” designed specifically for healthcare data.
The platform can:
- Analyze large volumes of patient information that doctors typically don’t have time to review
- Identify patterns that suggest someone is at risk for chronic diseases
- Recommend next steps for treatment or intervention
- Help insurers reduce their medical loss ratios
Why does it matter?
Chronic diseases are the biggest cost problem in global healthcare. They account for about 70% of deaths worldwide and more than $8 trillion in annual spending, according to the World Health Organization.
The problem isn’t a lack of health data – it’s that doctors can only review a tiny fraction of available information before making decisions. This means many conditions go undetected until they’re harder and more expensive to treat.
“Our customers are global from day one, because the problem is global from day one,” said Marius Klages, dehaze’s co-founder and CEO. “The speed at which payers are signing with us confirms what we believed when we started: this is a category that will be defined over the next few years, and dehaze is going to define it.”
The context
Healthcare AI is having a moment, but most attention has focused on chatbots and diagnostic imaging tools. Dehaze is betting on a different approach – using causal AI to tackle the economic side of healthcare by preventing expensive chronic diseases.
The company plans to use the new funding to expand its engineering, research, and commercial teams. It will also continue developing platform features like treatment recommendations and better traceability tools as it scales internationally.